AvastinBreastCancer posts

Feed

Option update 12-7-07: Genentech volatility settles

Genentech (NYSE: DNA) is recently down $1.43 to $68. The FDA's Oncologic Drugs Advisory Committee rejected Avastin for the use in breast cancer on December 5. DNA January option implied volatility spiked to 39 on Dec. 5. DNA January option implied volatility of 26 is near its 26-week average of 25 according to Track Data, suggesting non-directional price risk.

Costco (NASDAQ: COST) shares are near a record high. COST is expected to report Q1 EPS 59 cents on December 13, according to Thomson First Call. COST December 70 straddle is at $4.30. COST January option implied volatility of 29 is near its 26-week average according to Track Data, suggesting non-directional risk.

Daily Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Symbol Lookup
IndexesChangePrice
DJIA-74.9212,454.83
NASDAQ-1.852,837.53
S&P 500-2.861,317.82

Last updated: May 25, 2012: 10:48 PM

Hot Stocks

General Electric

19.20-0.05(-0.26)

Alcoa

8.630.00(0.00)

Apple Inc

562.29-3.03(-0.54)

Google Inc 'A'

591.53-12.13(-2.01)

Bank of America

7.15+0.01(+0.14)

Wal-Mart Stores

65.31+0.24(+0.37)

Exxon Mobil Corp

82.08-0.53(-0.64)

Ford

10.60+0.01(+0.09)

Citigroup

26.47-0.19(-0.71)

IBM

194.30-1.79(-0.91)

Yahoo

15.36+0.01(+0.07)

Starbucks

54.56-0.20(-0.37)

Microsoft

29.06-0.01(-0.03)

Home Depot

49.44-0.27(-0.54)

DailyFinance Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1338000494492 ms.